Concentra’s offer comes three weeks after Jounce signed an all-stock merger deal with U.K.-based Redx Pharma, which the companies expect to complete by the second quarter of 2023. The resulting combined entity will retain Redx’s name and therapeutic focuses: fibrotic diseases and cancer.

Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.